Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

515
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
515
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

628
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
628
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

414
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
414
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

Prioritising efficacy over convenience.

American journal of respiratory and critical care medicine·2026
Same author

AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.

The Journal of allergy and clinical immunology·2026
Same author

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

ERJ open research·2026
Same author

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Chest·2026
Same author

Benralizumab: Bringing winds of change to eosinophil-associated diseases.

The World Allergy Organization journal·2025
Same journal

Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.

Journal of asthma and allergy·2026
Same journal

Expression of miR-185-5p, miR-146b-5p, miR-320b, and miR-21-5p in Eosinophil Subtypes in Allergic Asthma Patients.

Journal of asthma and allergy·2026
Same journal

Development and Internal Evaluation of a Clinical-Physiological Model for Predicting Methacholine-Defined Airway Hyperresponsiveness in Children Aged 0-3 Years.

Journal of asthma and allergy·2026
Same journal

Allergen Sensitization Profiles and Co-Sensitization Networks in Children with Allergic Rhinitis and Asthma: A Propensity Score-Matched Retrospective Study.

Journal of asthma and allergy·2026
Same journal

Implementation of an Institutional Asthma Care Guideline in Hospitalized Children: Effects on Clinical Outcomes and Healthcare Resource Utilization.

Journal of asthma and allergy·2026
Same journal

Comorbidity of Allergic Asthma and Rhinitis and High Allergen-Specific IgE are Risk Factors for Systemic Reactions to House Dust Mite Immunotherapy in Children.

Journal of asthma and allergy·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K

Targeting TSLP in Asthma.

Jane R Parnes1, Nestor A Molfino1, Gene Colice2

  • 1Amgen, Thousand Oaks, CA, USA.

Journal of Asthma and Allergy
|June 10, 2022
PubMed
Summary
This summary is machine-generated.

Thymic stromal lymphopoietin (TSLP) inhibition with tezepelumab offers a novel approach for severe asthma. This treatment improves asthma control and reduces exacerbations across various phenotypes.

Keywords:
TSLPanti-TSLPasthmaexacerbation ratesthymic stromal lymphopoietin

More Related Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.5K
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

6.9K

Related Experiment Videos

Last Updated: Sep 20, 2025

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.5K
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
08:26

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

6.9K

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Thymic stromal lymphopoietin (TSLP) is a key epithelial cytokine driving asthma inflammation.
  • TSLP initiates innate and adaptive immune responses contributing to diverse asthma phenotypes.
  • Targeting TSLP presents a novel therapeutic strategy for managing asthma.

Purpose of the Study:

  • To review the safety and efficacy of tezepelumab, a TSLP inhibitor, in treating severe asthma.
  • To evaluate the impact of TSLP blockade on asthma control, exacerbations, and biomarkers.
  • To assess the broad-spectrum inhibitory effects of anti-TSLP therapy on asthma pathways.

Main Methods:

  • Review of recently published Phase 2 and Phase 3 clinical studies on tezepelumab.
  • Analysis of tezepelumab's efficacy in reducing asthma exacerbations and hospitalizations.
  • Assessment of clinical benefits correlated with changes in inflammatory biomarkers (e.g., IL-5, IL-13, eosinophils, IgE, FeNO).

Main Results:

  • Tezepelumab demonstrated safety and tolerability in patients with severe asthma.
  • Clinically meaningful improvements in asthma control were observed, including reduced exacerbations and hospitalizations.
  • Benefits were noted across eosinophilic and non-eosinophilic severe asthma phenotypes.
  • Reduced levels of key inflammatory cytokines and biomarkers were associated with tezepelumab treatment.

Conclusions:

  • TSLP inhibition via tezepelumab provides a broadly effective treatment for severe asthma.
  • Tezepelumab offers significant clinical benefits by targeting central pathways of airway inflammation.
  • Anti-TSLP therapy represents a promising approach for diverse asthma endotypes and phenotypes.